RenovaCare, Inc. Announces Appointment of Robert W. Cook as New Chief Financial Officer
June 16, 2020 at 06:00 pm IST
Share
RenovaCare, Inc. announced the appointment of Mr. Robert W. Cook as a new Chief Financial Officer. Mr. Robert W. Cook, who has more than 20 years of experience in senior financial leadership roles in healthcare, pharmaceuticals, and medical devices, and in the finance sector alone has completed more than $10 billion in transactions. Prior to his appointment as RenovaCare CFO, Mr. Cook served as Chief Financial Officer of CorMedix Inc., and previously at BioBlast Pharma Ltd., and Strata Skin Sciences. His executive roles at Immune Pharmaceuticals and EpiCept Corporation, included Interim President, CFO, and appointments to the Board of Directors. Previously he served as CFO of Pharmos Corporation raising more than $100 million in public financing to support R&D, where he negotiated and closed the sale of its ophthalmic business to Bausch & Lomb, advised by J.P. Morgan.
RenovaCare, Inc. is a clinical-stage biotechnology company. The Company is focused on developing autologous (self-donated) stem cell therapies for the regeneration of human organs. The Company through its wholly owned subsidiary, RenovaCare Sciences Corp. is focusing on the research, development and commercialization of autologous (using a patientâs own cells) cellular therapies that can be used for medical and aesthetic applications. The Companyâs CellMist System is a cell isolation procedure that enzymatically renders stem cells from the patientâs own skin or other tissues. The resulting stem cell suspension is administered topically from the Companyâs novel solution sprayer device (the SkinGun) as a cell therapy for wounds including burns to facilitate healing. Its SkinGun spray device is an advanced technology, using a gentle positive-pressure air stream to spray the CellMist Solution onto wounds.